JPMorgan views Oric Pharmaceuticals (ORIC)’ Phase 1b dose-escalation combination data for ORIC-944 plus AR inhibitor in metastatic castration-resistant prostate cancer as a “home run scenario.” The early ORIC-944 combination data “hits our home run scenario,” with clear signals of better PSA responses and better safety relative to the known data from the Xtandi plus mevrometostat update, the analyst tells investors in a research note. JPMorgan views Oric shares as “significantly undervalued” and sees potential to for the stock to “grind to mid-teens to high-teens with time.” It keeps an Overweight rating on Oric with a $20 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Buy Rating for Oric Pharmaceuticals Driven by Promising ORIC-944 Study Results and Undervaluation
- Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis
- Oric Pharmaceuticals Secures $125M in Private Placement
- Oric Pharmaceuticals announces preliminary efficacy, safety data from ORIC-944
- Oric Pharmaceuticals to sell 19.2M shares at $6.50 in private placement